- Home
- ROOT vs IRON Comparison
ROOT vs IRON Comparison
Compare ROOT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- IRON
- Stock Information
- Founded
- ROOT 2015
- IRON 2017
- Country
- ROOT United States
- IRON United States
- Employees
- ROOT N/A
- IRON N/A
- Industry
- ROOT Property-Casualty Insurers
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- IRON Health Care
- Exchange
- ROOT Nasdaq
- IRON Nasdaq
- Market Cap
- ROOT 2.1B
- IRON 1.9B
- IPO Year
- ROOT 2020
- IRON N/A
- Fundamental
- Price
- ROOT $136.93
- IRON $52.36
- Analyst Decision
- ROOT Buy
- IRON Strong Buy
- Analyst Count
- ROOT 7
- IRON 10
- Target Price
- ROOT $87.00
- IRON $83.80
- AVG Volume (30 Days)
- ROOT 835.8K
- IRON 339.8K
- Earning Date
- ROOT 04-29-2025
- IRON 05-08-2025
- Dividend Yield
- ROOT N/A
- IRON N/A
- EPS Growth
- ROOT N/A
- IRON N/A
- EPS
- ROOT 1.83
- IRON N/A
- Revenue
- ROOT $1,176,500,000.00
- IRON N/A
- Revenue This Year
- ROOT $9.56
- IRON N/A
- Revenue Next Year
- ROOT $12.72
- IRON N/A
- P/E Ratio
- ROOT $74.83
- IRON N/A
- Revenue Growth
- ROOT 158.57
- IRON N/A
- 52 Week Low
- ROOT $34.04
- IRON $25.60
- 52 Week High
- ROOT $181.14
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- ROOT 48.80
- IRON 43.50
- Support Level
- ROOT $147.01
- IRON $51.57
- Resistance Level
- ROOT $181.14
- IRON $53.61
- Average True Range (ATR)
- ROOT 13.24
- IRON 2.05
- MACD
- ROOT -1.93
- IRON 0.04
- Stochastic Oscillator
- ROOT 16.35
- IRON 31.17
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.